The company is initiating a clinical trial program in Canada evaluating an investigational use of nebulized antiviral Virazole in combination with standard of care therapy to treat hospitalized adult patients with respiratory distress due to COVID-19. The company ramped up manufacturing of chloroquine and azithromycin and donated these products to local hospitals in Italy and Spain.
Bausch is working toward investigative trials in the US to evaluate Xifaxan in combination therapy to potentially address the symptoms of gastrointestinal distress and pulmonary compromise associated with COVID-19 infection. Supply chain and manufacturing facilities are operational, and to date, Bausch Health has not had any material COVID-19 related supply disruptions.